ACS Clinical Research Program
Why is surgeon qualification important for clinical trials, and how can it be achieved?(Comments Off on Why is surgeon qualification important for clinical trials, and how can it be achieved?)
This month’s column underscores the importance of clinical trial participation, in particular surgeons who have a demonstrated capability and knowledge in conducting research-related operations.
Pancreatic cancer is the fourth-most common cause of cancer-related death in the U.S. and is predicted to soon be the third-leading cause. Surgical resection with pancreatectomy has historically been viewed as offering the only chance for cure. However, achieving negative margins at surgery can be difficult, with positive surgical margins found in as many as […]
This month’s column describes the role of diet and lifestyle on the development and outcomes of prostate cancer, and includes a brief overview of published and ongoing trials.
Research findings regarding the effect of metabolic response on gastric cancer are summarized, including the new Alliance 021302 trial.
Historically, neoadjuvant systemic therapy (NST) has been mainly used to convert breast cancer from inoperable to operable; however, today NST also is incorporated into the treatment of patients who initially present with operable disease. NST can allow some patients with stage II-III breast cancer who initially present with disease extent necessitating mastectomy to possibly undergo […]
More in this category
- Dissemination and implementation: Translating cancer guidelines and clinical trial outcomes into everyday practice
- Rectal cancer resection: Laparoscopic or open—which way forward?
- Prospective comparative effectiveness trial for malignant bowel obstruction: SWOG S1316
- Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options
- Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results
- Biomarker-driven adjuvant targeted therapy for NSCLC—the ALCHEMIST trials
- PACES trial: Evaluating the effectiveness of eflornithine and sulindac in preventing colon adenomas
- Multimodality treatment considerations in esophageal and gastric cancer: Are we making progress?
- New manual for cancer surgery issued: Operative Standards for Cancer Surgery
- Limited resection as a cure for early lung cancer: Time to challenge the gold standard?
- Progress in the PROSPECT trial: Precision treatment for rectal cancer?
- Colorectal cancer metastatic to the liver: Making the unresectable resectable
- QOL concerns in surgical patients: Assessment and intervention
- Treating metastatic prostate cancer now and in the future
- NCDB and ACS-CRP: Working together to develop risk-stratified strategies for surveillance